new independent report on hiv pipeline

only 1 nrti mentioned/analysed, with sales forecasts and impacts on revenue for ATC to 2018

sads, could you stump up the $11 400 for the report?


http://www.reportlinker.com/p0155079/Pipeline-Insight-HIV-The-Age-of-Convenience.html?utm_source=LivePR&utm_medium=pr&utm_campaign=LivePR
Pipeline Insight: HIV - The Age of Convenience

4. Pipeline Analysis & Forecasts: Nucleoside Reverse Transcriptase Inhibitors 64
Key findings 64
Overview for nucleoside reverse transcriptase inhibitors 65
Pipeline summary 65
Comparative forecasts 66
Apricitabine (Avexa) 67
Drug overview 67
Clinical trial data 68
Phase III 68
Phase II studies 69
Clinical and commercial attractiveness 71
Positioning in treatment experienced patients will limit uptake 71
Commercialization of apricitabine may prove difficult without a suitable partner 72
SWOT analysis 73
Datamonitor drug assessment score card for apricitabine 73
Satisfaction of unmet needs 75
Resistance 75
Toxicity 75
Target product profile 75
Forecasts to 2018 76
Other drugs in the nucleoside reverse transcriptase class 77
Elvucitabine 77
Amdoxovir 78


Table 19: Key products in the R&D pipeline for the NRTI class, 2009 66
Table 20: Sales forecasts for NRTIs in the US and five major European markets ($m), 2009-19 67
Table 21: Apricitabine - drug profile, 2009 68
Table 22: Overview of 48-week efficacy data from AVX-201 71
Table 23: Ability of apricitabine to meet unmet needs 76
Table 24: Sales forecasts for apricitabine in the US and 5EU ($m), 2009-18 76
Table 25: Impacting factors on the revenues of apricitabine, 2009-18 77
Table 26: Other drugs in the nucleoside reverse transcriptase class, 2009 77